manag
sever
communityacquir
pneumonia
veronica
brito
michael
niederman
communityacquir
pneumonia
cap
major
caus
infectionrel
death
develop
countri
also
common
etiolog
system
sepsi
critic
ill
mortal
rate
sever
communityacquir
pneumonia
scap
far
higher
mortal
observ
pneumonia
manag
outsid
hospit
hospit
outsid
intens
care
unit
icu
therefor
ensur
proper
manag
therapi
imper
recogn
ill
soon
possibl
delay
recogn
sever
form
cap
increas
mortal
inde
number
studi
show
delay
manag
icu
associ
higher
risk
death
diseas
manag
expectantli
icu
first
sign
sever
ill
uniformli
use
accept
definit
scap
standard
criteria
admiss
icu
current
infecti
diseas
societi
america
american
thorac
societi
idsaat
guidelin
defin
scap
use
major
criteria
respiratori
failur
need
assist
ventil
septic
shock
requir
vasopressor
three
addit
minor
criteria
use
diagnos
scap
respiratori
rate
breathsminut
higher
pao
fio
ratio
less
multilobar
infiltr
confus
disorient
blood
urea
nitrogen
bun
mgdl
higher
leukopenia
white
blood
cell
count
cell
mm
thrombocytopenia
plateletsmm
hypothermia
temperatur
c
hypotens
requir
aggress
fluid
resuscit
possibl
minor
criteria
affect
decis
admit
patient
icu
includ
hypoglycemia
nondiabet
patient
alcohol
withdraw
hyponatremia
unexplain
metabol
acidosi
lactic
acidosi
asplenia
although
attempt
develop
object
criteria
scap
case
seri
defin
entiti
simpli
cap
requir
admiss
icu
one
studi
nation
databas
unit
kingdom
cap
account
icu
admiss
earli
admiss
appear
prefer
set
sever
ill
mortal
rate
admit
icu
within
day
hospit
admiss
rose
admit
day
admit
day
hospit
admiss
studi
shown
improv
outcom
scap
initi
therapi
appropri
retrospect
french
studi
use
multivari
analysi
demonstr
effect
initi
therapi
appear
signific
prognost
factor
fact
prognost
factor
constitut
modifi
medic
intervent
risk
factor
sever
form
communityacquir
pneumonia
patient
scap
coexist
ill
convers
patient
chronic
ill
increas
likelihood
develop
complic
pneumon
ill
tabl
common
chronic
ill
patient
respiratori
diseas
chronic
obstruct
lung
diseas
copd
cardiovascular
diseas
diabet
mellitu
addit
certain
habit
cigarett
smoke
alcohol
abus
also
common
scap
inde
cigarett
smoke
identifi
risk
factor
bacterem
pneumococc
infect
common
ill
cap
includ
malign
neurolog
disord
includ
seizur
milder
form
pneumonia
may
sever
present
patient
receiv
antibiot
therapi
hospit
admiss
addit
abil
contain
infecti
challeng
may
relat
genet
differ
immun
respons
may
predispos
certain
individu
sever
form
infect
advers
outcom
may
reflect
famili
histori
sever
pneumonia
advers
outcom
infect
appear
like
scap
result
inflamm
either
insuffici
contain
infect
exuber
host
respons
affect
uninvolv
lung
lead
acut
respiratori
distress
syndrom
system
circul
lead
sever
sepsi
commonli
use
predictor
outcom
pneumonia
two
score
system
pneumonia
sever
index
psi
british
thorac
societi
rule
latter
rule
recent
modifi
score
acronym
follow
confus
serum
urea
nitrogen
level
higher
mgdl
respiratori
rate
breathsminut
higher
low
systol
mm
hg
diastol
mm
hg
blood
pressur
age
older
year
two
score
system
valid
identifi
patient
low
risk
mortal
howev
limit
limit
appar
system
use
identifi
scap
ideal
two
complement
one
anoth
psi
heavili
weight
age
comorbid
necessarili
measur
sever
acut
ill
reli
vital
sign
abnorm
fall
either
dichotom
variabl
threshold
thu
may
overestim
sever
ill
older
patient
underestim
sever
younger
individu
without
comorbid
ill
convers
criteria
may
adequ
consid
presenc
comorbid
ill
particularli
pneumonia
induc
decompens
sever
studi
compar
prognost
tool
popul
one
recent
studi
psi
good
predict
mortal
identifi
lowrisk
patient
howev
appear
discrimin
defin
mortal
risk
sever
ill
anoth
studi
colleagu
use
psi
evalu
larg
number
inpati
outpati
cap
investig
simpler
version
exclud
measur
bun
thu
use
outpati
accur
predict
mortal
need
mechan
ventil
perhap
need
hospit
addit
criteria
correl
time
clinic
stabil
thu
higher
score
predict
longer
durat
intraven
therapi
longer
length
hospit
stay
psi
predict
mortal
howev
demonstr
studi
psi
good
predict
need
icu
admiss
colleagu
found
also
could
predict
need
icu
admiss
reliabl
howev
investig
found
although
still
limit
accur
psi
predict
need
icu
admiss
studi
done
tertiari
care
hospit
spain
patient
highest
possibl
psi
categori
risk
class
v
treat
medic
ward
treat
icu
investig
found
patient
admit
icu
tend
get
psi
point
acut
rather
chronic
ill
revers
true
psi
class
v
patient
admit
icu
data
patient
cap
admit
two
tertiari
hospit
texa
analyz
retrospect
demonstr
although
patient
icu
higher
psi
score
ward
patient
icu
patient
cohort
patient
includ
patient
psi
class
fall
lowrisk
psi
group
class
iii
find
similar
data
report
ewig
associ
indic
psi
good
predict
cap
mortal
determin
need
icu
care
prognost
tool
use
identifi
need
intens
care
predict
mortal
summar
tabl
recent
colleagu
tri
develop
specif
rule
icu
admiss
examin
record
patient
determin
need
icu
admiss
defin
presenc
one
two
major
criteria
arteri
ph
less
systol
blood
pressur
less
mm
hg
absenc
criteria
scap
also
could
identifi
presenc
two
six
minor
criteria
includ
confus
bun
greater
mgdl
respiratori
rate
greater
breathsminut
pao
fio
ratio
less
multilobar
infiltr
age
least
year
criteria
met
tool
sensit
identifi
scap
accur
psi
criteria
although
quit
specif
rule
number
recent
investig
examin
biomark
serum
measur
cap
sever
predict
outcom
studi
focus
creactiv
protein
crp
procalcitonin
pct
cortisol
studi
patient
inpati
outpati
pct
measur
within
hour
diagnosi
cap
level
correl
psi
score
higher
class
iii
v
ii
develop
complic
higher
empyema
mechan
ventil
septic
shock
level
also
increas
die
compar
serial
measur
pct
also
use
defin
prognosi
scap
patient
investig
report
nonsurvivor
significantli
higher
pct
level
survivor
day
serial
measur
survivor
decreas
pct
level
wherea
nonsurvivor
increas
day
recent
studi
patient
present
emerg
depart
switzerland
pneumonia
cortisol
level
also
could
use
predict
sever
ill
outcom
death
free
total
cortisol
level
correl
sever
ill
reflect
psi
score
level
total
cortisol
nmoll
sensit
specif
predict
mortal
data
view
cautious
recent
studi
question
reliabl
serum
cortisol
level
patient
acut
septic
ill
histori
focu
presenc
symptom
suggest
respiratori
infect
fever
cough
purul
sputum
pleurit
chest
pain
dyspnea
along
inform
suggest
seriou
ill
histori
thu
focu
presenc
comorbid
ill
recent
hospit
recent
antibiot
therapi
addit
certain
clinic
condit
associ
specif
pathogen
patient
cap
associ
evalu
obtain
histori
tabl
exampl
present
subacut
follow
contact
bird
rat
rabbit
possibl
psittacosi
leptospirosi
tularemia
plagu
consid
coxiella
burnetii
q
fever
concern
exposur
parturi
cat
cattl
sheep
goat
francisella
tularensi
concern
rabbit
exposur
hantaviru
exposur
mice
drop
endem
area
chlamydia
psittaci
exposur
turkey
infect
bird
legionella
speci
exposur
contamin
water
sourc
sauna
influenza
superinfect
pneumococcu
staphylococcu
aureu
includ
methicillinresist
aureu
mrsa
haemophilu
influenza
consid
travel
endem
area
asia
onset
respiratori
failur
viral
ill
lead
suspicion
viral
pneumonia
could
sever
acut
respiratori
syndrom
sar
avian
influenza
endem
fungi
coccidioidomycosi
histoplasmosi
blastomycosi
occur
welldefin
geograph
area
may
present
acut
symptom
overlap
acut
bacteri
pneumonia
physic
find
pneumonia
includ
tachypnea
crackl
rhonchi
sign
consolid
egophoni
bronchial
breath
sound
dull
percuss
patient
also
evalu
sign
pleural
effus
addit
extrapulmonari
find
sought
rule
metastat
infect
arthriti
endocard
mening
add
suspicion
atyp
pathogen
mycoplasma
pneumonia
chlamydophila
pneumonia
lead
complic
bullou
myring
skin
rash
pericard
hepat
hemolyt
anemia
meningoenceph
attent
physic
examin
may
help
identifi
patient
sever
pneumonia
one
studi
show
elderli
patient
elev
respiratori
rate
initi
present
sign
pneumonia
preced
clinic
find
much
day
inde
tachypnea
present
patient
found
often
elderli
younger
patient
pneumonia
addit
count
respiratori
rate
identifi
patient
sever
ill
commonli
rate
higher
breathsminut
addit
constel
suggest
clinic
featur
diagnosi
cap
made
find
although
controversi
valu
diagnost
test
patient
cap
extens
routin
test
recommend
admit
icu
sever
studi
shown
establish
etiolog
diagnosi
improv
outcom
scap
outcom
improv
empir
broadspectrum
earli
therapi
given
target
like
etiolog
pathogen
howev
diagnost
test
may
valu
purpos
narrow
focus
therapi
guid
manag
patient
respond
empir
therapi
collect
sampl
diagnost
test
import
start
empir
antibiot
delay
therapi
associ
increas
mortal
addit
chest
radiograph
scap
patient
blood
lower
respiratori
tract
sputum
endotrach
aspir
bronchoalveolar
lavag
bronchoscop
specimen
cultur
arteri
blood
ga
analysi
routin
hematolog
blood
chemistri
test
patient
moderates
pleural
effus
tap
fluid
sent
cultur
biochem
analysi
yield
posit
cultur
pleural
fluid
low
inform
acquir
cultur
posit
substanti
effect
manag
antibiot
choic
also
indic
drainag
patient
scap
two
set
blood
cultur
like
posit
patient
receiv
antibiot
time
sampl
sign
liver
diseas
hypotens
fever
hypothermia
tachycardia
puls
beatsminut
elev
bun
serum
sodium
level
less
meql
white
cell
count
lower
cellsml
higher
cellsml
presenc
bacteremia
may
worsen
prognosi
allow
identif
drugresist
organ
although
posit
blood
cultur
cap
reveal
pneumococcu
sputum
cultur
accompani
gram
stain
guid
interpret
cultur
result
focu
initi
antibiot
therapi
situat
gram
stain
use
broaden
initi
empir
therapi
enhanc
suspicion
organ
cover
routin
empir
therapi
aureu
suggest
cluster
gramposit
cocci
especi
time
epidem
influenza
routin
serolog
test
recommend
howev
patient
sever
ill
diagnosi
legionella
speci
infect
made
urinari
antigen
test
test
like
posit
time
admiss
one
shortcom
test
specif
serogroup
infect
examin
concentr
urin
pneumococc
antigen
also
may
valuabl
case
viral
etiolog
suspect
influenza
direct
fluoresc
antibodi
test
perform
result
usual
avail
hour
respiratori
virus
test
might
use
particularli
set
outbreak
bronchoscopi
indic
routin
diagnost
test
may
need
patient
sever
form
cap
establish
etiolog
diagnosi
order
focu
initi
broadspectrum
empir
therapi
simpler
regimen
patient
sever
pneumonia
admit
hospit
outpati
contact
health
care
environ
thu
tradit
cap
rather
diagnosi
health
careassoci
pneumonia
hcap
patient
admit
nurs
home
extend
care
facil
hospit
sometim
past
day
undergon
hemodialysi
receiv
ongo
wound
care
contact
hospit
environ
patient
risk
infect
multidrugresist
mdr
gramneg
pathogen
mrsa
thu
need
differ
approach
therapi
idsaat
nosocomi
pneumonia
guidelin
hcap
consid
form
nosocomi
infect
medicar
exempt
patient
therapi
compliant
cap
core
measur
chosen
includ
hcap
discuss
cap
patient
develop
sever
ill
risk
infect
enter
gramneg
bacteria
mrsa
howev
patient
admit
nurs
home
still
may
infect
caus
atyp
pathogen
legionella
speci
patient
hcap
pathogen
similar
scap
wherea
other
pathogen
similar
sever
nosocomi
pneumonia
therapi
vari
accordingli
exampl
hcap
patient
high
risk
mdr
pathogen
prior
antibiot
exposur
within
past
month
poor
function
statu
recent
hospit
common
caus
scap
pneumococcu
streptococcu
pneumonia
organ
account
two
third
bacterem
pneumonia
frequent
caus
lethal
cap
least
case
resist
penicillin
antibiot
lead
term
drugresist
pneumonia
drsp
current
penicillin
resist
unit
state
intermedi
type
penicillin
minimum
inhibitori
concentr
mic
mgl
rather
highlevel
type
penicillin
mic
pneumococc
resist
antibiot
includ
macrolid
trimethoprimsulfamethoxazol
also
common
clinic
relev
effect
outcom
vitro
find
uncertain
one
studi
corrobor
opinion
mani
expert
found
organ
penicillin
mic
higher
mgl
associ
increas
risk
death
prospect
intern
studi
patient
pneumococc
bacteremia
vitro
resist
blactam
associ
littl
way
clinic
impact
discord
therapi
penicillin
cefotaxim
ceftriaxon
result
higher
mortal
howev
discord
therapi
cefuroxim
led
wors
clinic
outcom
organ
sensit
agent
although
drsp
common
quinolon
resist
unusu
doern
associ
observ
although
penicillin
resist
present
pneumococci
quinolon
resist
rare
howev
organ
singl
firststep
mutat
par
c
confer
resist
could
predispos
clinic
resist
presenc
second
mutat
gyr
situat
mandat
close
observ
patient
scap
consid
risk
drsp
addit
admit
icu
infect
atyp
pathogen
account
infect
either
primari
infect
copathogen
ident
organ
vari
time
geographi
area
legionella
speci
common
caus
scap
wherea
other
c
pneumonia
pneumonia
infect
predomin
import
caus
scap
includ
h
influenza
aureu
mrsa
especi
influenza
enter
gramneg
bacteria
includ
p
aeruginosa
risk
factor
gramneg
bacteria
includ
underli
copd
especi
corticosteroid
therapi
recent
hospit
prior
antibiot
bronchiectasi
presenc
hcap
specif
risk
p
aeruginosa
includ
presenc
structur
lung
diseas
bronchiectasi
copd
treatment
broadspectrum
antibiot
within
day
present
chronic
steroid
use
malign
malnutrit
rapid
radiograph
spread
diseas
also
clue
presenc
p
aeruginosa
infect
multicent
spanish
studi
patient
scap
patient
p
aeruginosa
rapidli
progress
ill
antimicrobi
treatment
admiss
inadequ
recent
toxinproduc
strain
mrsa
describ
patient
cap
influenza
viral
infect
communityacquir
mrsa
biolog
genet
distinct
mrsa
caus
nosocomi
pneumonia
virul
necrot
associ
product
pantonvalentin
leukocidin
pvl
virus
caus
scap
culprit
includ
influenza
viru
well
parainfluenza
viru
epidem
virus
coronaviru
caus
sar
avian
influenza
viral
pneumonia
sar
influenza
lead
respiratori
failur
occasion
tuberculosi
endem
fungi
result
sever
pneumonia
unusu
etiolog
consid
patient
epidemiolog
risk
factor
specif
pathogen
discuss
previous
addit
presenc
certain
modifi
factor
increas
likelihood
cap
caus
drsp
gramneg
bacteria
risk
factor
drsp
includ
blactam
therapi
past
month
alcohol
age
older
year
immun
suppress
multipl
medic
comorbid
contact
child
day
care
risk
factor
gramneg
bacteria
mention
previous
includ
presenc
hcap
addit
aspir
commonli
associ
gramneg
pneumonia
anaerob
infect
institution
elderli
popul
treatment
icuadmit
cap
initi
therapi
direct
drsp
legionella
speci
atyp
pathogen
enter
gramneg
bacteria
includ
p
aeruginosa
select
organ
drug
select
base
appropri
histor
epidemiolog
data
therapi
stratifi
depend
whether
patient
risk
p
aeruginosa
base
risk
factor
list
previous
treatment
algorithm
icuadmit
cap
patient
receiv
empir
monotherapi
even
one
new
quinolon
recommend
base
fact
efficaci
especi
mening
complic
pneumonia
effect
dose
safeti
singl
agent
includ
quinolon
monotherapi
establish
icuadmit
cap
patient
one
recent
studi
compar
highdos
levofloxacin
blactamquinolon
combin
singleag
regimen
overal
effect
howev
patient
septic
shock
exclud
trend
wors
outcom
monotherapi
individu
treat
mechan
ventil
anoth
studi
scap
use
blactammacrolid
combin
surviv
advantag
compar
quinolon
monotherapi
patient
pseudomon
risk
factor
therapi
limit
select
intraven
blactam
cefotaxim
ceftriaxon
ertapenem
blactamblactamas
inhibitor
combin
combin
either
intraven
macrolid
intraven
antipneumococc
quinolon
levofloxacin
moxifloxacin
patient
pseudomon
risk
factor
therapi
twodrug
regimen
use
antipseudomon
blactam
imipenem
meropenem
piperacillintazobactam
cefepim
plu
ciprofloxacin
activ
antipseudomon
quinolon
levofloxacin
mg
daili
altern
threedrug
regimen
involv
antipseudomon
blactam
plu
aminoglycosid
plu
either
intraven
antipneumococc
quinolon
levofloxacin
moxifloxacin
macrolid
use
one
justif
familiar
recommend
find
patient
treat
type
regimen
outcom
improv
sever
studi
shown
guidelin
complianc
improv
outcom
nonadher
lead
delay
clinic
resolut
regimen
altern
clear
whether
one
regimen
better
anoth
howev
select
empir
therapi
regimen
necessari
know
antibiot
patient
receiv
within
past
month
choos
agent
differ
class
inde
repeat
use
class
antibiot
may
drive
resist
class
especi
pathogen
pneumococcu
one
studi
use
penicillin
cephalosporin
trimethoprimsulfa
levofloxacin
month
preced
pneumococc
bacteremia
led
increas
likelihood
bacterem
pathogen
would
resist
recent
use
therapeut
agent
addit
choos
antibiot
therapi
discuss
previous
import
give
first
dose
antibiot
soon
possibl
diagnosi
establish
patient
cap
time
administr
antibiot
reduc
mortal
especi
true
first
dose
given
within
hour
even
rapid
administr
necessari
sever
ill
exampl
patient
sepsi
hour
delay
start
antibiot
therapi
increas
mortal
antibiot
regimen
discuss
previous
cover
atyp
pathogen
use
either
macrolid
quinolon
data
indic
approach
reduc
mortal
especi
sever
ill
even
patient
pneumococc
bacteremia
use
combin
therapi
gener
addit
typic
pathogen
coverag
pneumococc
coverag
associ
reduc
mortal
rel
monotherapi
one
studi
benefit
ad
second
agent
appli
pneumococc
bacteremia
patient
critic
ill
popul
rodriguez
colleagu
found
benefit
ad
second
agent
patient
scap
shock
benefit
appli
agent
ad
either
macrolid
quinolon
certain
adjunct
therapi
consid
although
recommend
strategi
less
support
evid
includ
oxygen
chest
physiotherapi
least
ml
sputum
daili
poor
cough
respons
aerosol
bronchodil
corticosteroid
hypotens
possibl
rel
adren
insuffici
suspect
analysi
use
activ
protein
c
patient
septic
shock
demonstr
patient
pivot
clinic
trial
underli
cap
activ
protein
c
effect
cap
patient
acut
physiolog
chronic
health
evalu
apach
ii
score
higher
psi
class
iv
v
score
least
also
benefit
pneumococc
infect
inadequ
therapi
although
benefit
minim
treat
adequ
therapi
corticosteroid
may
help
scap
immunomodul
effect
one
random
control
trial
patient
compar
hydrocortison
infus
mgday
placebo
found
steroid
therapi
reduc
mortal
length
stay
durat
mechan
ventil
anoth
recent
studi
involv
retrospect
analysi
patient
scap
base
psi
score
receiv
system
corticosteroid
reason
pneumonia
treat
cap
therapi
system
corticosteroid
found
independ
associ
decreas
mortal
larg
random
control
studi
need
make
recommend
routin
use
corticosteroid
scap
data
suggest
steroid
use
danger
therapi
need
reason
patient
scap
data
proper
durat
therapi
patient
cap
especi
sever
ill
even
presenc
pneumococc
bacteremia
short
durat
therapi
may
possibl
also
may
possibl
rapidli
switch
intraven
oral
therapi
respond
patient
gener
pneumonia
treat
day
patient
respond
rapidli
receiv
accur
empir
therapi
correct
dose
presenc
extrapulmonari
infect
eg
mening
empyema
identif
certain
pathogen
eg
bacterem
aureu
p
aeruginosa
may
suggest
need
longer
durat
therapi
treatment
legionella
pneumophila
pneumonia
may
requir
day
therapi
recent
data
howev
suggest
quinolon
therapi
may
best
approach
manag
treatment
littl
day
levofloxacin
mg
may
effect
switch
oral
therapi
even
sever
ill
patient
may
facilit
use
quinolon
agent
highli
bioavail
achiev
serum
level
oral
therapi
intraven
therapi
controversi
need
empir
therapi
direct
communityacquir
mrsa
expert
recommend
organ
target
empir
therapi
patient
sever
necrot
cap
follow
viral
ill
particularli
influenza
optim
therapi
defin
vancomycin
alon
may
suffici
led
clinic
failur
presum
activ
pvl
toxin
accompani
communityacquir
mrsa
reason
may
necessari
add
clindamycin
vancomycin
use
linezolid
rifampin
sever
ill
latter
agent
inhibit
toxin
product
overal
patient
hospit
cap
respond
initi
therapi
mortal
increas
nonrespond
patient
admit
icu
risk
failur
respond
high
mani
patient
experi
deterior
even
initi
stabil
icu
pneumonia
clinic
syndrom
patient
diagnosi
actual
lung
infect
inde
may
infect
unusu
nonsuspect
pathogen
addit
patient
develop
complic
ill
therapi
situat
may
lead
appar
nonrespons
therapi
nonrespond
patient
evalu
altern
diagnos
inflammatori
lung
diseas
atelectasi
heart
failur
malign
pulmonari
hemorrhag
pulmonari
embolu
nonpneumon
infect
resist
unusu
pathogen
includ
tuberculosi
fungal
infect
pneumonia
complic
empyema
lung
abscess
drug
fever
antibioticinduc
coliti
secondari
site
infect
central
line
infect
intraabdomin
infect
tabl
search
specif
etiolog
agent
evalu
one
studi
chang
antibiot
regimen
base
microbiolog
studi
oppos
empir
chang
alter
mortal
nonrespond
although
patient
respond
therapi
rapidli
sever
pneumonia
tend
protract
cours
evalu
nonrespond
patient
individu
may
includ
comput
tomographi
chest
pulmonari
angiographi
bronchoscopi
occasion
openlung
biopsi
bronchoscopi
may
valuabl
immunocompromis
immunosuppress
patient
help
identifi
presenc
pneumocysti
speci
virus
fungi
mycobacteri
infect
recognit
scap
earliest
possibl
time
point
improv
outcom
uniformli
accept
definit
scap
prognost
score
system
psi
decis
support
tool
diagnost
test
scap
focu
histor
data
increas
risk
infect
specif
pathogen
obtain
chest
radiograph
blood
cultur
sputum
cultur
urinari
antigen
test
legionella
pneumococcu
speci
patient
scap
need
therapi
drugresist
pneumococcu
atyp
pathogen
includ
legionella
speci
consider
risk
factor
enter
gramneg
bacteria
includ
p
aeruginosa
patient
especi
diagnos
influenza
risk
mrsa
patient
come
nurs
home
hcap
may
risk
drugresist
organ
patient
scap
requir
combin
therapi
base
whether
patient
risk
p
aeruginosa
patient
receiv
empir
monotherapi
adjunct
therapi
scap
includ
chest
physiotherapi
consider
corticosteroid
immun
modul
activ
protein
c
